Skip to main content

Table 1 The Clinical Characteristics of the 75 patients

From: Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Parameter   Value
Gender-no.(%) No. of Male(%) 48 (64.0%)
No.of Female(%) 27 (36.0%)
Mean age-mean ± SD (yr) All subjects 48.8 ± 14.1
Male 49.0 ± 13.5
Female 48.4 ± 15.4
Body mass index-mean ± SD (kg/m2) 27.5 ± 11.2
ECOG performance status-no.(%) 0 18 (24.0%)
1 57 (76.0%)
CEA Level-mean ± SD (ng/ml) Pre-Immunotherapy 160.2 ± 411.3
Post-Immunotherapy 284.4 ± 890.5
CA199 Level-mean ± SD (ng/ml) Pre-Immunotherapy 387.3 ± 1271.7
Post-Immunotherapy 512.8 ± 2037.1
Previous therapies-no.(%) Surgery 53 (70.7%)
Chemotherapy 73 (97.3%)
Radiotherapy 13 (17.3%)
Target cancer therapy 49 (65.3%)